Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Utility and Generalizability of Multistate, Population-Based Cancer Registry Data for Rural Cancer Surveillance Research in the United States.

Zahnd WE, Jenkins WD, James AS, Izadi SR, Steward DE, Fogleman AJ, Colditz GA, Brard L.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1252-1260. doi: 10.1158/1055-9965.EPI-17-1087. Epub 2018 Mar 21.

PMID:
29563132
2.

Rural-urban differences in surgical treatment, regional lymph node examination, and survival in endometrial cancer patients.

Zahnd WE, Hyon KS, Diaz-Sylvester P, Izadi SR, Colditz GA, Brard L.

Cancer Causes Control. 2018 Feb;29(2):221-232. doi: 10.1007/s10552-017-0998-4. Epub 2017 Dec 27.

3.

Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.

Ayyagari VN, Diaz-Sylvester PL, Hsieh TJ, Brard L.

PLoS One. 2017 Sep 20;12(9):e0185111. doi: 10.1371/journal.pone.0185111. eCollection 2017.

4.

Rural-Urban Differences in Cancer Incidence and Trends in the United States.

Zahnd WE, James AS, Jenkins WD, Izadi SR, Fogleman AJ, Steward DE, Colditz GA, Brard L.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1265-1274. doi: 10.1158/1055-9965.EPI-17-0430. Epub 2017 Jul 27.

PMID:
28751476
5.

Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer.

Alanee S, Delfino K, Wilber A, Robinson K, Brard L, Semaan A.

Pharmacogenet Genomics. 2017 Jul;27(7):264-269. doi: 10.1097/FPC.0000000000000288.

6.

Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.

Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L.

BMC Cancer. 2017 Jan 13;17(1):49. doi: 10.1186/s12885-016-3034-2.

7.

Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.

Ayyagari VN, Johnston NA, Brard L.

Anticancer Drugs. 2016 Jul;27(6):547-59. doi: 10.1097/CAD.0000000000000364.

8.

Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease.

Brodsky AS, Fischer A, Miller DH, Vang S, MacLaughlan S, Wu HT, Yu J, Steinhoff M, Collins C, Smith PJ, Raphael BJ, Brard L.

PLoS One. 2014 Apr 14;9(4):e94476. doi: 10.1371/journal.pone.0094476. eCollection 2014.

9.

Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action.

Ayyagari VN, Brard L.

BMC Cancer. 2014 Feb 4;14:61. doi: 10.1186/1471-2407-14-61.

10.

PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models.

Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KA, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, Brard L, Singh RK.

Genes Cancer. 2013 Nov;4(11-12):524-34. doi: 10.1177/1947601913507575.

11.

Identification of ovarian cancer metastatic miRNAs.

Vang S, Wu HT, Fischer A, Miller DH, MacLaughlan S, Douglass E, Comisar L, Steinhoff M, Collins C, Smith PJ, Brard L, Brodsky AS.

PLoS One. 2013;8(3):e58226. doi: 10.1371/journal.pone.0058226. Epub 2013 Mar 12. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/aeb6ccee-921a-4250-a18c-4ea633b984dd. Comisar, Lauren [added].

12.

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.

Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS.

Gynecol Oncol. 2012 Oct;127(1):141-6. doi: 10.1016/j.ygyno.2012.06.028. Epub 2012 Jun 26.

PMID:
22750258
13.

7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells.

Kristjansdottir K, Kim K, Choi JS, Horan TC, Brard L, Moore RG, Singh RK.

Gynecol Oncol. 2012 Aug;126(2):252-8. doi: 10.1016/j.ygyno.2012.04.041. Epub 2012 May 2.

PMID:
22561404
14.

Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.

Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK.

PLoS One. 2012;7(4):e34443. doi: 10.1371/journal.pone.0034443. Epub 2012 Apr 3.

15.

Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.

Kim KK, Lange TS, Singh RK, Brard L, Moore RG.

BMC Cancer. 2012 Apr 13;12:147. doi: 10.1186/1471-2407-12-147.

16.

WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.

Yoshioka S, King ML, Ran S, Okuda H, MacLean JA 2nd, McAsey ME, Sugino N, Brard L, Watabe K, Hayashi K.

Mol Cancer Res. 2012 Mar;10(3):469-82. doi: 10.1158/1541-7786.MCR-11-0177. Epub 2012 Jan 9.

17.

Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells.

Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N, Singh RK.

Int J Oncol. 2012 Jan;40(1):99-108. doi: 10.3892/ijo.2011.1225. Epub 2011 Oct 6.

PMID:
21994123
18.

Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells.

Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK.

Chem Biol Drug Des. 2012 Jan;79(1):92-103. doi: 10.1111/j.1747-0285.2011.01251.x. Epub 2011 Nov 4.

PMID:
21974809
19.

Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells.

Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG.

Int J Oncol. 2012 Jan;40(1):227-35. doi: 10.3892/ijo.2011.1198. Epub 2011 Sep 12.

PMID:
21922132
20.

T0901317 inhibits cisplatin-induced apoptosis in ovarian cancer cells [corrected].

Miller DH, Fischer AK, Chu KF, Burr R, Hillenmeyer S, Brard L, Brodsky AS.

Int J Gynecol Cancer. 2011 Nov;21(8):1350-6. doi: 10.1097/IGC.0b013e318228f558. Erratum in: Int J Gynecol Cancer. 2011 Dec;21(9):1711.

21.

Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.

Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK.

Gynecol Oncol. 2011 Nov;123(2):370-8. doi: 10.1016/j.ygyno.2011.07.002. Epub 2011 Jul 30.

PMID:
21803404
22.

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS.

BMC Cancer. 2011 Jul 22;11:308. doi: 10.1186/1471-2407-11-308.

23.

Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation.

Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS.

PLoS One. 2011 Apr 29;6(4):e19049. doi: 10.1371/journal.pone.0019049.

24.

Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro.

Singh RK, Dorf L, DeMartino A, Illenye S, Koto K, Currier EA, Ashikaga T, Kim KK, Brard L, Sholler GL.

Cancer Biol Ther. 2011 Jun 15;11(12):1036-45. Epub 2011 Jun 15.

PMID:
21532338
25.

Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.

Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG.

Gynecol Oncol. 2011 Jul;122(1):183-9. doi: 10.1016/j.ygyno.2011.03.035. Epub 2011 May 6.

PMID:
21529906
26.

Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma.

Koto KS, Lescault P, Brard L, Kim K, Singh RK, Bond J, Illenye S, Slavik MA, Ashikaga T, Saulnier Sholler GL.

Int J Oncol. 2011 May;38(5):1329-41. doi: 10.3892/ijo.2011.971. Epub 2011 Mar 10.

PMID:
21399873
27.

A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.

Saulnier Sholler GL, Bergendahl GM, Brard L, Singh AP, Heath BW, Bingham PM, Ashikaga T, Kamen BA, Homans AC, Slavik MA, Lenox SR, Higgins TJ, Ferguson WS.

J Pediatr Hematol Oncol. 2011 Jan;33(1):25-30. doi: 10.1097/MPH.0b013e3181f47061.

PMID:
21063221
28.

Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model.

Lange TS, Zou Y, Singh RK, Kim KK, Kristjansdottir K, Sholler GL, Brard L.

Chem Biol Drug Des. 2010 Aug;76(2):164-73. doi: 10.1111/j.1747-0285.2010.00988.x. Epub 2010 May 11.

29.

Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.

Kim KK, Lange TS, Singh RK, Brard L.

BMC Cancer. 2010 Feb 25;10:72. doi: 10.1186/1471-2407-10-72.

30.

Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model.

Lange TS, McCourt C, Singh RK, Kim KK, Singh AP, Luisi BS, Alptürk O, Strongin RM, Brard L.

Drug Des Devel Ther. 2009 Sep 21;3:17-26.

32.

A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.

Singh RK, Lange TS, Kim KK, Brard L.

Invest New Drugs. 2011 Feb;29(1):63-72. doi: 10.1007/s10637-009-9335-4. Epub 2009 Oct 29.

33.

Effect of a vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model.

Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA, Brard L.

Invest New Drugs. 2010 Oct;28(5):543-53. doi: 10.1007/s10637-009-9284-y. Epub 2009 Jul 7.

34.

Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?

McCourt C, Dessie S, Bradley AM, Schwartz J, Brard L, Dizon DS.

Int J Gynecol Cancer. 2009 Apr;19(3):343-7. doi: 10.1111/IGC.0b013e3181a12eb9.

PMID:
19407557
35.

Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo.

Saulnier Sholler GL, Brard L, Straub JA, Dorf L, Illeyne S, Koto K, Kalkunte S, Bosenberg M, Ashikaga T, Nishi R.

J Pediatr Hematol Oncol. 2009 Mar;31(3):187-93. doi: 10.1097/MPH.0b013e3181984d91.

36.

Cranberry proanthocyanidins are cytotoxic to human cancer cells and sensitize platinum-resistant ovarian cancer cells to paraplatin.

Singh AP, Singh RK, Kim KK, Satyan KS, Nussbaum R, Torres M, Brard L, Vorsa N.

Phytother Res. 2009 Aug;23(8):1066-74. doi: 10.1002/ptr.2667.

37.

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells.

Singh RK, Lange TS, Kim KK, Singh AP, Vorsa N, Brard L.

Br J Cancer. 2008 Dec 2;99(11):1823-31. doi: 10.1038/sj.bjc.6604778. Epub 2008 Nov 11.

38.

Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.

Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L.

PLoS One. 2008 May 28;3(5):e2303. doi: 10.1371/journal.pone.0002303. Erratum in: PLoS ONE. 2008;3(7). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31.

39.

For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?

Dizon DS, Restivo A, Lomme M, Charbonneau N, Brard L, Hughes T, Weitzen S, Legare R, Granai CO, Disilvestro P.

Am J Clin Oncol. 2008 Feb;31(1):39-42. doi: 10.1097/COC.0b013e318134ee6f.

PMID:
18376226
40.

A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.

Singh RK, Lange TS, Kim KK, Shaw SK, Brard L.

Gynecol Oncol. 2008 May;109(2):240-9. doi: 10.1016/j.ygyno.2008.01.042. Epub 2008 Mar 7.

41.

Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial.

Moore RG, Robison K, Brown AK, DiSilvestro P, Steinhoff M, Noto R, Brard L, Granai CO.

Gynecol Oncol. 2008 Apr;109(1):65-70. doi: 10.1016/j.ygyno.2007.12.027. Epub 2008 Feb 5.

PMID:
18255128
42.

Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma.

Lange TS, Singh RK, Kim KK, Zou Y, Kalkunte SS, Sholler GL, Swamy N, Brard L.

Chem Biol Drug Des. 2007 Oct;70(4):302-10.

43.

Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines.

Singh RK, Lange TS, Kim K, Zou Y, Lieb C, Sholler GL, Brard L.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5846-52. Epub 2007 Aug 19.

44.

Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.

Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, Dizon DS.

Gynecol Oncol. 2007 Apr;105(1):81-3. Epub 2006 Dec 8.

PMID:
17157366
45.

Benzyl isothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro.

Kalkunte S, Swamy N, Dizon DS, Brard L.

J Exp Ther Oncol. 2006;5(4):287-300.

PMID:
17024969
46.

Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation.

Satyan KS, Swamy N, Dizon DS, Singh R, Granai CO, Brard L.

Gynecol Oncol. 2006 Oct;103(1):261-70. Epub 2006 Apr 19.

PMID:
16624391
47.

The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.

Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO.

Gynecol Oncol. 2006 Oct;103(1):176-80. Epub 2006 Mar 27.

PMID:
16564074
48.

Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.

Kalkunte S, Brard L, Granai CO, Swamy N.

Angiogenesis. 2005;8(4):349-60. Epub 2006 Jan 7.

PMID:
16400520
49.

Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes.

Robison K, Steinhoff MM, Granai CO, Brard L, Gajewski W, Moore RG.

Gynecol Oncol. 2006 Apr;101(1):24-7. Epub 2005 Oct 24.

PMID:
16246399
50.

Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma.

Brard L, Granai CO, Swamy N.

Gynecol Oncol. 2006 Jan;100(1):116-27. Epub 2005 Oct 3.

PMID:
16203029

Supplemental Content

Support Center